← Back to Search

Monoclonal Antibodies

Brentuximab Vedotin + Nivolumab for Hodgkin's Lymphoma

Phase 3
Recruiting
Led By Kara M Kelly
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial compares adding immunotherapy to standard chemo/radiation for Hodgkin lymphoma to improve survival.

Who is the study for?
This trial is for patients aged 5-60 with newly diagnosed, untreated classical Hodgkin lymphoma stages I or II. They must have proper kidney and liver function, no severe lung conditions, not be on high-dose steroids or immunosuppressants, and not have other active serious illnesses. Pregnant women and those who haven't agreed to use effective contraception are excluded.
What is being tested?
The study compares standard chemotherapy (with drugs like doxorubicin and prednisone) plus radiation against the same treatment combined with immunotherapy drugs Brentuximab Vedotin and Nivolumab. The goal is to see if adding these two drugs improves survival rates.
What are the potential side effects?
Possible side effects include immune system reactions, infusion-related responses, fatigue, nausea, hair loss from chemo; Brentuximab may cause nerve damage; Nivolumab can lead to inflammation in organs like lungs or intestines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PFS in slow-early responder (SER) patients
Progression-free survival (PFS) in rapid early responder (RER) patients
Secondary study objectives
Contribution of SDOH to OS by race and ethnicity
Contribution of SDOH to PFS by race and ethnicity
Effect of metabolic tumor burden (MTV) on PFS
+14 more
Other study objectives
Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement
Association between FDG PET parameters obtained by automated measurements and PFS
Association between self-reported race/ethnicity and dimensional SDOH
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Group I: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)Experimental Treatment13 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm B.
Group II: Arm G (ABVD, eBEACOPP or eBPDac, ISRT)Experimental Treatment18 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.
Group III: Arm F (ABVD, brentuximab vedotin, nivolumab)Experimental Treatment12 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
Group IV: Arm E (ABVD, AVD)Experimental Treatment10 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
Group V: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)Experimental Treatment13 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
Group VI: Arm C (ABVD, eBEACOPP or eBPDac, ISRT)Experimental Treatment18 Interventions
See Detailed Description.
Group VII: Arm B (ABVD, brentuximab vedotin, nivolumab)Experimental Treatment12 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
Group VIII: Arm A (ABVD)Active Control10 Interventions
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prednisolone
2005
Completed Phase 4
~3570
Computed Tomography
2017
Completed Phase 2
~2790
Cyclophosphamide
2010
Completed Phase 4
~2310
Dacarbazine
2005
Completed Phase 3
~5270
Doxorubicin Hydrochloride
2019
Completed Phase 3
~17860
Etoposide
2010
Completed Phase 3
~2960
Etoposide Phosphate
2011
Completed Phase 2
~160
Magnetic Resonance Imaging
2017
Completed Phase 3
~1180
Nivolumab
2015
Completed Phase 3
~4010
Positron Emission Tomography
2011
Completed Phase 2
~2200
Prednisone
2014
Completed Phase 4
~2500
Procarbazine Hydrochloride
2010
Completed Phase 2
~170
Vinblastine Sulfate
2007
Completed Phase 4
~300
Vincristine Sulfate
2005
Completed Phase 3
~10270
Biospecimen Collection
2004
Completed Phase 3
~2030
Bleomycin Sulfate
2010
Completed Phase 3
~1960
Brentuximab Vedotin
2015
Completed Phase 3
~1080

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,958 Previous Clinical Trials
41,110,705 Total Patients Enrolled
Kara M KellyPrincipal InvestigatorRoswell Park Cancer Institute
1 Previous Clinical Trials
150 Total Patients Enrolled
Tara O HendersonPrincipal InvestigatorChildren's Oncology Group
1 Previous Clinical Trials
376 Total Patients Enrolled

Media Library

Brentuximab Vedotin (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05675410 — Phase 3
Hodgkin's Lymphoma Research Study Groups: Arm C (ABVD, eBEACOPP or eBPDac, ISRT), Arm G (ABVD, eBEACOPP or eBPDac, ISRT), Arm A (ABVD), Arm B (ABVD, brentuximab vedotin, nivolumab), Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT), Arm E (ABVD, AVD), Arm F (ABVD, brentuximab vedotin, nivolumab), Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)
Hodgkin's Lymphoma Clinical Trial 2023: Brentuximab Vedotin Highlights & Side Effects. Trial Name: NCT05675410 — Phase 3
Brentuximab Vedotin (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05675410 — Phase 3
~1250 spots leftby Apr 2031